Meeting to be held in Connecticut on June 18 hosted by Oppenheimer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Corbus Pharmaceuticals price target raised to $82 from $77 at RBC Capital
- Corbus Pharmaceuticals’ Promising Cancer Drug Trial Results
- Corbus Pharmaceuticals price target raised to $80 from $60 at Oppenheimer
- SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024
- Corbus Pharmaceuticals updated Phase 1 data for SYS-6002 to be presented at ASCO